ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 306

Children with Probable SLE by ACR Criteria May Need More Aggressive Lupus Treatment Early in the Disease Course

Anjali Patwardhan1, Igor Dvorchik2 and Charles H. Spencer3, 1Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 2Biostatistics Division, Nationwide Children's Hospital,, Columbus, OH, 3Rheumatology, Nationwide Childrens Hospital, Columbus, OH

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis, Neuroimaging, outcome measures and steroids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: This research explores whether delay of the childhood-onset SLE (cSLE) diagnosis until 4/11 ACR criteria are met affects patient outcome negatively

Methods: Institutional Review Board approval was obtained to retrospectively review the charts of 98 SLE patients seen in the rheumatology clinic at Nationwide Children’s Hospital over the past 24 years. All the patients were divided in to two groups, ‘definitive cSLE’ – who met the minimum 4/11 or more ACR criteria at presentation in rheumatology clinic and the ‘probable cSLE’ who did not meet the minimum criteria. Both the groups were assessed for disease severity, damage and gradient of damage. Appropriate statistical tests were used, i.e. Chi-Square test, Fisher’s Exact test, Univariate logistic regression and Wilcoxon two-sample test were utilized. All tests were conducted in SAS 9.2

Results: Out of 98 cSLE patients, 71 % were included in definitive cSLE (DcSLE) group while 29 % were included in probable cSLE (PcSLE) group. The mean time for PcSLE group to reach DcSLE status was 20.3 months There was no difference in the ethnic distribution (p=0.7370). PcSLE were more likely to have a higher male: female ratio (p=0.032), and were older at presentation that DcSLE (p=0.045). PcSLE patients were less likely to have internal organ involvement (7.1% vs. 25.7%), were less likely to be hospitalized and receive pulse steroids (P=0.0142) or oral steroids (0.0172) at presentation. PcSLE patients were less likely to be hospitalized to receive pulse steroids ever (p=0.0628), were less likely to have renal disease ever (p=0.0653) and nervous system disease ever (p=0.0182). PcSLE was more likely to receive hydroxychloroquine (p=0.050). The organ damage was assessed using SLICC/ACR damage index at 1, 5 and 10 years post diagnosis. The maximum damage was recorded within first 5 years of the diagnosis. Initial damage was predictive of later damage. D pSLE had higher disease damage scores at 5 and 10 years. We compared the gradient between the onsets of symptoms and the development of organ damage in the two groups. The PcSLE patients had significantly higher internal organ damage gradient as compared to DcSLE (p value=0.0169)

Conclusion: In our population, PcSLE patients had a significantly high gradient of damage than the DcSLE group. In spite of D pSLE being more severe diseases ever and more diseases damage, the disease damage progression was steeper and faster in PpSLE. This may be explained by the fact that PpSLE patients received a less intense treatment regimen at presentation than DcSLE group. It may be that PcSLE patients need just as early vigorous treatment as the children with DcSLE


Disclosure:

A. Patwardhan,
None;

I. Dvorchik,
None;

C. H. Spencer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/children-with-probable-sle-by-acr-criteria-may-need-more-aggressive-lupus-treatment-early-in-the-disease-course/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology